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Abstract  53 
 54 
Familial medullary thyroid cancer (MTC) and its precursor, C cell hyperplasia (CCH), is associated 55 
with germline RET mutations causing multiple endocrine neoplasia type 2. However, some rare 56 
families with apparent MTC/CCH predisposition do not have a detectable RET mutation. To identify 57 
novel MTC/CCH predisposition genes we undertook exome resequencing studies in a family with 58 
apparent predisposition to MTC/CCH and no identifiable RET mutation. We identified a novel ESR2 59 
frameshift mutation, c.948delT, which segregated with histological diagnosis following thyroid 60 
surgery in family members and demonstrated loss of ESR2 encoded ERβ expression in the MTC 61 
tumour. ERα and ERβ form heterodimers binding DNA at specific estrogen response elements (ERE) 62 
to regulate gene transcription. ERβ represses ERα mediated activation of the ERE and the RET 63 
promoter contains three ERE. In vitro, we showed that ESR2 c.948delT results in unopposed ERα 64 
mediated increased cellular proliferation, activation of the ERE and increased RET expression. In 65 
vivo, immunostaining of CCH and MTC using an anti-RET antibody demonstrated increased RET 66 
expression. Together these findings identify germline ESR2 mutation as a novel cause of familial 67 
MTC/CCH and provide important insights into a novel mechanism causing increased RET expression 68 
in tumourigenesis.   69 
 70 
 71 
 72 
 73 
 74 
 75 
 76 
 77 
  78 
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Introduction 79 
 80 
Thyroid cancer is the most common endocrine malignancy. Although medullary thyroid 81 
cancer (MTC), arising from the calcitonin secreting para-follicular cells, only accounts for ~5% of 82 
thyroid cancers (1), nearly 50% of patients present with stage III or IV disease and only 21% of 83 
patients presenting with stage IV disease survive 10 years (2). 84 
In ~25% of MTC there is a germline RET mutation (3) predisposing to multiple endocrine 85 
neoplasia type 2 (MEN2), a dominantly inherited endocrine tumour predisposition syndrome 86 
characterised by predisposition to the development of young onset MTC and often primary C cell 87 
hyperplasia (CCH), a precursor to MTC (4). Other features may also occur such as 88 
phaeochromocytoma, primary hyperparathyroidism (HPT) and, rarely, developmental abnormalities, 89 
for example, a marfanoid habitus and ganglioneuromatosis of the mouth and gut (4).  90 
The majority of RET mutations predisposing to MEN2 result in single amino acid 91 
substitutions affecting key residues in the extra-cellular and kinase domains of the RET receptor (5,6) 92 
causing inappropriate constitutive RET activation. Detection of a germline RET mutation, enables 93 
pre-symptomatic interventions such as prophylactic thyroidectomy to be offered to at-risk gene 94 
carriers (6). Thus all individuals presenting with MTC or primary CCH should be offered germline 95 
RET testing (7); however, some families with an apparent predisposition to MTC/CCH do not harbour 96 
a germline RET gene alteration (8,9) suggesting that further predisposing gene alterations remain to be 97 
identified. We investigated a kindred with non-RET MTC/CCH and detected a novel constitutional 98 
frameshift mutation in ESR2 encoding the beta subunit of the oestrogen receptor, ERβ (10).   99 
  100 
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Results 101 
 102 
Case Report  103 
The index case presented age 22 years with MTC (Supplementary Material, Fig. S1). 104 
Although no constitutional mutation of exons 10, 11, or 13-16 of RET was detected, in view of the 105 
young age of diagnosis his monozygotic twin brother was offered follow-up and underwent 106 
thyroidectomy age 33 years because of abnormal pentagastrin stimulation testing; histological review 107 
showed the presence of CCH. Prophylactic thyroid surgery was then undertaken in the offspring of 108 
both brothers (individuals III:1-5); individuals III:2 and III:3 were found to have CCH and individuals 109 
III:1, III:4 and III:5 to have normal thyroid tissue. Pentagastrin stimulation testing was subsequently 110 
offered to the wider family and individual I:1 noted to have mildly abnormal results. In the index case, 111 
further constitutional molecular genetic testing did not detect any mutations in the remaining exons of 112 
RET, karyotype analysis was normal and array CGH analysis did not demonstrate any clinically 113 
significant CNVs (data not shown). We therefore hypothesised a novel gene alteration was 114 
predisposing to MTC/CCH in the family and undertook exome sequencing in two affected members 115 
(II:3 and III:3). 116 
 117 
Identification of Germline ESR2 mutation in Familial MTC/CCH  118 
We filtered the variants identified using the dbSNP (11), NHLBI Exome Variant Server 119 
(EVS) (12) and 1000 genomes (13) datasets looking for potentially disrupting variants present in both 120 
samples, prioritising frameshift and nonsense changes. We did not identify any deleterious alterations 121 
in the genes known to be mutated in hereditary cancer predisposition (14, Supplementary Material, 122 
Table S1) but did identify a novel frameshift alteration of ESR2 (c.948delT; p.Gly318Alafs*22) 123 
present in both affected individuals but not in the NHLBI EVS nor in 2577 individuals from the 1000 124 
genome project (12,13).  125 
Constitutional ESR2 sequencing in other family members demonstrated the c.948delT variant 126 
to be present in the two family members found to have CCH (individuals II:1 and III:2) but not in the 127 
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three (individuals III:1, III:4, III:5) with normal thyroid histology (Fig. 1A, Supplementary Material, 128 
Fig. S1). 129 
 130 
Loss of ERβ staining in ESR2 c.948delT associated MTC 131 
To investigate the role of ESR2 in MTC tumourigenesis we initially undertook 132 
immunohistochemistry using an anti-ERβ antibody and demonstrated complete loss of nuclear 133 
staining in the c.948delT associated MTC (Fig. 1B) with retained staining in the corresponding 134 
normal thyroid tissue.  However, despite direct sequencing of the complete ESR2 coding region and 135 
LOH studies using closely linked microsatellite markers in archived tumour material, we did not 136 
detect a somatic alteration of ESR2 (data not shown). Whole genome copy number analysis by 137 
molecular inversion probe technology did not reveal any pathological CNVs affecting either 138 
chromosomes 14 or 10 (harbouring the ESR2 and RET loci respectively) (Supplementary Material, 139 
Fig. S2).  140 
 141 
No additional constitutional ESR2 mutations in other cases of apparent MTC predisposition   142 
To ascertain whether constitutional alterations of ESR2 might be involved in other cases of 143 
apparent MTC predisposition, we undertook sequencing of the coding region of ESR2 in 19 144 
individuals with apparently isolated MTC, eight of whom were diagnosed <40 years of age (mean age 145 
at diagnosis 47.5y, range 33-71y, SEM 2.96). The entire coding region of RET had been previously 146 
sequenced and no alterations detected other than known polymorphisms. We identified a novel 147 
germline missense alteration, c.382G>C; p.V128L, in a female who developed an apparently isolated 148 
MTC age 36 years (Fig. 2A). This variant was also detected in a pair of siblings, one of whom had a 149 
papillary thyroid cancer age 60 years and the other a medullary thyroid cancer age 57 years. We did 150 
not detect any constitutional ESR2 alterations, other than known polymorphisms, in a further three 151 
families with familial non-RET MTC (data not shown). 152 
Further investigation using archived tumour material from the individual with the apparently 153 
isolated MTC and ESR2 c.382G>C (no blocks were available from the sibling pair) revealed 154 
preserved ERβ staining (Fig. 2B) and no somatic ESR2 sequence alterations, LOH or pathological 155 
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CNVs of chromosomes 14 or 10 were detected. Although this variant was not present in the NHLBI 156 
EVS (12) or 1000 genome project (13) datasets, further analysis using SIFT (15) predicted it to be 157 
tolerated, and PolyPhen-2 (16) to be benign; we were therefore unable to exclude that ESR2 158 
c.382G>C may represent a rare polymorphism and did not evaluate further. 159 
 160 
No somatic mutations of ESR2 detected in sporadic MTC  161 
As hereditary cancer predisposing genes are often implicated in sporadic tumours (17), we 162 
investigated whether somatic mutations of ESR2 also occurred in sporadic MTC. However, direct 163 
sequencing of ESR2 in 15 fresh frozen sporadic MTC did not reveal any alterations other than known 164 
polymorphisms (data not shown). Whilst the cosmic (18) and TCGA data sets (19), containing data 165 
for over 21,000 tumours, did not have any data regarding ESR2 in MTC, we did note the presence of 166 
somatic ESR2 mutations in other tumours of neuroectodermal origin, for example glioma and 167 
melanoma.  168 
 169 
ESR2 c.948delT is associated with unrestrained ERα driven cell proliferation 170 
We then sought to understand how this rare novel ESR2 frameshift alteration might cause 171 
tumourigenesis. Initially we determined stability of the ESR2 c.948delT mutant compared to wild-172 
type (wt) ESR2. Transient transfection of HCT116 cells, followed by the addition of the transcription 173 
inhibitor, actinomycin, resulted in significantly lower ESR2 c.948delT mRNA levels over a 24 hour 174 
time period compared with wtESR2 indicating reduced stability of the mutant mRNA (Supplementary 175 
Material, Fig. S3). 176 
ESR2-encoded ERβ forms either homo- or, preferentially, hetero-dimers with ESR1-encoded 177 
ERα to bind DNA at specific estrogen-responsive elements (EREs) within the promoters of target 178 
genes to regulate transcription (20). ERα is the more potent activator and ERβ can repress ERα; thus 179 
transcriptional activity is determined by the relative ERα/ERβ proportion (21-23). 180 
We next investigated whether ESR2 c.948delT altered cellular growth. In MCF-7 cells, ESR2 181 
c.948delT failed to restrain the ERα-driven proliferation of MCF-7 cells in response to either 17β-182 
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estradiol (E2) or the ERα selective agonist, PPT. In contrast, wtESR2 was capable of inhibiting cell 183 
proliferation by up to 30% in both E2 and PPT treated MCF7 cells over-expressing ERα (Fig. 3). 184 
 185 
Loss of ERβ function causes increased estrogen-responsive element (ERE) activity and RET 186 
expression  187 
In both HCT116 and MCF-7 cells, in response to either E2 or PPT agonist, wtESR1 activated 188 
the ERE, as indicated by increased luciferase expression, and this was significantly restrained in the 189 
presence of wtESR2. However, co-transfection of wtESR1 with ESR2 c.948delT restored expression 190 
to a level similar to that seen with wtESR1 alone indicating that the ESR2 c.948delT mutant has lost 191 
the ability to restrain ERα-mediated activation of the ERE (Fig. 4).   192 
We then investigated how inappropriate activation of the ERE by c.948delT might cause 193 
MTC tumourigenesis. Inappropriate up-regulation of RET activity causing MTC is well established 194 
(4) and we noted that the RET promoter (-34 to -314) contains three ERE (24). Furthermore, in in 195 
vitro studies, RET has been established as an ER target gene (25-27). We therefore investigated 196 
whether loss of ERβ function might lead to up-regulation of RET expression. 197 
As MCF7 cells have intrinsic ER activity, we used HCT116 cells to investigate the effect of 198 
ESR2 c.948delT on RET expression. Co-transfection of wtESR1 with wtESR2 in HCT116 cells, in the 199 
presence of either E2 or PPT, resulted in decreased RET expression as compared with wtESR1 alone; 200 
however, over-expression of wtESR1 and ESR2 c.948delT, restored RET expression to a level similar 201 
to that seen with wtESR1 alone (Fig. 5A, B). 202 
 In vivo, RET immunostaining using archived sections from the ESR2 c.948delT associated 203 
MTC (individual II:3) and analysis of archived stained slides showing CCH (individual II:1) 204 
demonstrated increased RET staining (Fig. 5C). In particular, the intensity of RET expression in the 205 
MTC was stronger than in corresponding normal thyroid tissue and similar to that in an MEN2-206 
associated MTC with a known constitutional RET mutation (Fig. 5C). Analysis of RET exons 10, 11 207 
and 13-16 in the ESR2 c.948delT associated MTC did not detect a somatic mutation to account for the 208 
increased expression (data not shown).  209 
  210 
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Discussion 211 
By targeted capture array-based exome sequencing we detected a novel loss of function ESR2 212 
mutation in a family with predisposition to MTC/CCH. As the interpretation of novel rare variants 213 
identified through next generation sequencing approaches in isolated families is challenging, we 214 
sought functional evidence to establish pathogenicity. 215 
Initially we demonstrated tumour specific loss of ERβ expression in the c.948delT associated 216 
MTC which we considered indicative of loss of function as ERβ is known to be expressed by human 217 
para-follicular C cells (28). Whilst ESR2 knockout mice display a phenotype more in keeping with a 218 
reduced fertility phenotype in females rather than one associated with tumourigenesis (29), ESR2 has 219 
been shown to inhibit cell proliferation in vitro (30) and tumour formation in nude mice (31). 220 
Although we did not identify a somatic ESR2 alteration in this tumour and were unable to investigate 221 
ESR2 promoter hypermethylation, we note that ESR2 promoter hypermethylation associated with 222 
ERβ down-regulation has been detected in a variety of tumour types (32-34). As with other cancer 223 
predisposition syndromes (35), it is also probable that additional somatic mutations are required in the 224 
transition from normal thyroid to MTC and we did detect low level loss of chromosomes 3 and 13.  225 
It is likely that ERβ loss of function in MTC is rare as we did not detect loss of ERβ 226 
expression in 12 apparently sporadic MTC tumours nor an intragenic ESR2 mutation in 15 sporadic 227 
MTCs. Interestingly, studies of MTC have indicated that RAS and RET are the dominant driver 228 
pathways in tumourigenesis, with few mutations being detected in other genes and none in ESR2 (36). 229 
Our findings are also in keeping with large scale studies of sporadic tumours where no CNVs, and 230 
only one putative mutation of ESR2 (missense alteration in a single papillary thyroid cancer), have 231 
been detected in thyroid tumours (18,19). Such relative infrequency of somatic mutation in sporadic 232 
tumours in genes predisposing to hereditary cancers is well recognised, for example the low rate of 233 
somatic BRCA1 and BRCA2 mutations in sporadic breast cancer (37,38). We did note that somatic 234 
ESR2 mutations have been detected in other neuroectodermal derived tumours such as glioma and 235 
melanoma and also breast cancer samples indicating that inappropriate up-regulated ERα activity may 236 
also be involved in their tumourigenesis (18,19). 237 
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We did not detect a constitutional ESR2 mutation in a further three families with an apparent 238 
genetic predisposition to MTC and CCH and it is likely that, akin to other familial cancer 239 
predisposition syndromes (39), there is also heterogeneity in the genetic predisposition to MTC/CCH.  240 
The association of increased RET activity with MTC tumourigenesis is well established (4) 241 
and here we demonstrate a novel mechanism of MTC tumourigenesis whereby loss of ERβ function 242 
results in ERα-driven RET expression, likely mediated through the ERE on the RET promoter. Whilst 243 
there may be an unidentified constitutional RET mutation, or another mechanism of RET up-244 
regulation, we have also shown ESR2 c.948delT to cause increased cellular proliferation indicating a 245 
likely role in tumourigenesis; however, we cannot exclude that other mechanisms of ERβ action may 246 
also be involved, for example through loss of ERβ mediated inhibition of HIF-1α causing 247 
inappropriate HIF pathway activation (40). 248 
Although we detected a mutation in just one family, our results suggest that constitutional 249 
ESR2 mutation is of high penetrance for CCH/MTC. However, as individual I:1 has not overtly 250 
presented with MTC, we cannot exclude that there may be variable penetrance, as occurs for germline 251 
RET mutations and in other familial cancer predisposition syndromes such as paraganglioma-252 
phaeochromocytoma predisposition (4, 41).  253 
It is interesting to speculate whether constitutional ESR2 mutations are also associated with 254 
predisposition to HPT and phaeochromocytoma. These tumours have not occurred to date in the 255 
family (relevant clinical and laboratory investigation has been undertaken) and whole exome 256 
sequencing of both constitutional DNA from individuals with apparent genetic predisposition to 257 
phaeochromocytoma (12 individuals) and sporadic phaeochromocytoma (seven tumours) has not 258 
detected any deleterious ESR2 mutations (ERM unpublished observations). Nonetheless, given the 259 
known tumour predisposition associated with dysregulated RET activity, it would seem prudent to 260 
offer clinical surveillance for phaeochromocytoma and HPT, and prophylactic thyroidectomy, where a 261 
loss of function constitutional ESR2 mutation is detected. 262 
The investigation of rare familial cancer predisposition often provides important insights into 263 
cell biology with the potential for novel therapeutic approaches (42) and our findings also provide 264 
further evidence of the interaction between ERα and RET in tumourigenesis. Many invasive breast 265 
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cancers expressing ERα also express RET (4) and in recent pre-clinical models of breast cancer, 266 
targeting both RET and ERα decreases the growth and metastatic potential of breast cancer cells (43). 267 
Thus tumours associated with loss of ERβ function might be suitable candidates for therapeutic agents 268 
targeting the RET pathway (44),  RET tyrosine kinase active site (45) or ERα (46).   269 
In summary, our data is the first to identify a novel genetic cause for familial MTC since the 270 
identification of the RET gene. We demonstrate a novel mechanism promoting up-regulation of RET 271 
activity through constitutional ESR2 mutation which provides opportunities for pre-symptomatic 272 
testing and potential novel therapeutic strategies.  273 
 274 
  275 
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Materials and Methods 276 
 277 
Whole Exome Sequencing Analysis 278 
Exome sequencing was performed at the Biomedical Research Centre at Kings College 279 
London as previously described (47). 280 
 281 
Sanger Sequencing 282 
Genomic DNA was extracted from formalin-fixed paraffin embedded (FFPE) tissue using the 283 
QIAamp DNA FFPE kit (Qiagen) and from peripheral leucocytes using the Nucleon BACC2 kit 284 
(Amersham Biosciences) (sequences and PCR conditions available upon request).  285 
 286 
Immunohistochemistry 287 
Slides were de-paraffinized using Benchmark Special Stains Deparaffinization Solution. 288 
Heat-induced antigen retrieval was performed using EDTA buffer as previously described (48). 289 
Immunostaining was performed using the Ventana Benchmark Automated Slide Stainer (Ventana 290 
Medical Systems) with antibodies against ERβ (Leica Biosystems, 1:50), calcitonin (Dako IR515) and 291 
RET (Abcam EPR2871, 1:500).  292 
 293 
Loss of Heterozygosity (LOH) analyses 294 
Microsatellite markers were used to determine LOH at the ESR2 locus on chromosome 295 
14q23.2: one, previously described (49) within intron six (chr14:64,720,279-64,720,323) and one 5’ 296 
upstream (chr14:64,802,692-64,802,742) (sequences available upon request). PCR amplification was 297 
performed on genomic DNA templates using fluorescently labelled primers. PCR products were 298 
electrophoresed on an ABI Genetic Analyzer and analysed by GeneMapper fragment analysis 299 
software (Applied Biosystems).  300 
 301 
OncoScan® FFPE Assay Kit 302 
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The OncoScan® FFPE assay kit platform was utilized to identify whole-genome copy number 303 
variations (CNV) as previously described (50).  304 
 305 
Cell Culture  306 
In the absence of a suitable MTC cell line we used HCT116 (Health Protection Agency 307 
Culture Collections, UK) and MCF-7 cells (European Collection of Animal Cell Cultures) cultured in 308 
McCoy’s 5A (Life Technologies) with 5% fetal bovine serum (Invitrogen), penicillin (104 U/ml) and 309 
streptomycin (104 mcg/ml) (Invitrogen) for HCT116 cells and RPMI 1640 (Life Technologies) with 310 
5% fetal bovine serum (Invitrogen), penicillin (105 U/L) and streptomycin (100 mg/L) for MCF-7 311 
cells. Cells were treated with 17β-oestradiol (E2, Sigma) and 4,4’,4’’-(4-propyl-[1H]-pyrazole-1,3,5-312 
triyl(trisphenol) (PPT, Tocris)  at final concentrations of 10 nM and 100 nM, in phenol red-free 313 
medium (Life Technologies) with 5% charcoal-stripped serum. 314 
 315 
Transfection 316 
The ESR1/2 ORFS were cloned into Sgf1 and Mlu1 restriction sites of pCMV6-AN-Myc 317 
(Origene). QuikChange II XL site-directed mutagenesis kit (Agilent Technologies) was used to delete 318 
the thymine at position 948 of ESR2, generating ESR2, c.948delT. Plasmid DNA transfections were 319 
performed with TransIT LT1 (Mirus Bio LLC). In some experiments, plasmid DNA was introduced 320 
into cells by reverse transfection (lipid: DNA complexes plated prior to addition of cells). 321 
 322 
RNA extraction, Real-time PCR and mRNA Stability Assay 323 
Total RNA was extracted and reverse transcribed using RNeasy Micro Kit (Qiagen) and 324 
Reverse Transcription System (Promega) with expression determined by the 7500 Real-time PCR 325 
system (Applied Biosystems). qRT-PCR was carried out on 96 well plates using FAM-labelled 326 
Taqman probes (Life Technologies) for ESR2 (Hs01100359_m1), RET (Hs01120030_m1) and PPIA 327 
(Hs04194521_s1). In mRNA stability experiments, HCT116 cells were treated with actinomycin D at 328 
a final concentration of 10 µg/ml for 4h, 8h and 24h prior to total RNA extraction. 329 
 330 
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Western Blotting 331 
Western blots, performed as described previously (51), were probed with antibodies against 332 
RET (C31B4, Cell Signaling Technology), 1:1000; ERβ (H150, Santa Cruz Biotechnology), 1:1000; 333 
c-Myc, 1:1000 and β actin; 1:10,000 (Sigma-Aldrich). Antigen-antibody complexes were detected 334 
using ECL Plus (Amersham Biosciences).  335 
 336 
Luciferase Reporter Assays 337 
Luciferase reporter assays were performed using the Cignal ERE Reporter Kit (Qiagen). 338 
HCT116 (7,500 cells/ well) and MCF-7 (15,000 cells/ well) cells were reverse transfected with 50ng 339 
Cignal ERE reporter along with 100ng ER expression vectors with TransIT LT1. After 24h hormone 340 
incubation, cells were harvested with lysis buffer (Promega) and the firefly and renilla luciferase 341 
activities determined with a dual luciferase assay kit (Promega), measuring luminescence with a 342 
Centro LB960 microplate luminometer (Berthold Technologies). 343 
 344 
Cell Proliferation 345 
Proliferation of MCF-7 cells was determined using the Celltiter-Glo® Luminescent Cell 346 
Viability Assay (Promega). In brief, 12,500 MCF-7 cells were reverse transfected with ER expression 347 
vectors and TransIT LT1 in 96 wells and then treated with hormones as indicated for 72h prior to 348 
analysis of the luminescent signal using the Centro LB960 microplate luminometer (Berthold 349 
Technologies). 350 
 351 
Statistical Analyses 352 
Data are displayed as mean ± SE. Normally distributed data were analysed using a two-tailed 353 
Student’s t-test, unless otherwise indicated. A P-value < 0.05 was considered to be statistically 354 
significant.  355 
 356 
  357 
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Figure legends 523 
Figure 1. Germline ESR2 mutation detected in family members with MTC/CCH and loss of ERβ 524 
staining in associated MTC tumour. (A) Sanger sequencing traces showing presence of ESR2 525 
c.948delT (upper panel) and corresponding normal trace (lower panel). Affected nucleotide is 526 
indicated by a red arrow. (B) Representative histological stains in sections following thyroid surgery 527 
in representative family members II:3 (MTC), III:2 (CCH), III:4 (normal thyroid). Haematoxylin and 528 
eosin stain showing MTC (upper panel) and apparently normal thyroid tissue (middle and lower 529 
panels). Calcitonin staining demonstrating MTC (upper panel), areas of CCH within apparently 530 
normal thyroid tissue (black arrowhead, middle panel), and normal thyroid tissue (lower panel). ERβ 531 
immunohistochemistry showing loss of nuclear expression in the MTC (upper panel, white 532 
arrowhead). Middle and lower panels – preserved nuclear staining of ERβ in follicular epithelial cells. 533 
It was not possible to determine if there was loss of ERβ staining associated with areas of CCH 534 
(middle panel).   535 
 536 
Figure 2. Germline ESR2 alteration detected in an individual with early onset MTC and preserved 537 
ERβ staining in associated MTC tumour. (A) Sanger sequencing traces showing constitutional ESR2 538 
alteration c.382G>C (upper panel) and corresponding normal trace (lower panel) detected in an 539 
individual with apparently isolated MTC age 36 years. Affected nucleotide is indicated by a red 540 
arrow. (B) Representative histological stains in sections following thyroid surgery. Left, haematoxylin 541 
and eosin stain showing MTC (white arrowhead) and corresponding normal thyroid tissue (black 542 
arrowhead). Middle, calcitonin stain demonstrating MTC (white arrowhead) with corresponding 543 
unstained normal thyroid tissue (black arrowhead). Right, ERβ immunohistochemistry showing 544 
preserved nuclear expression in both MTC (white arrowhead and high power insert) and 545 
corresponding normal thyroid tissue (black arrowhead and high power insert).  546 
 547 
Figure 3. ESR2 c.948delT is associated with unrestrained ERα-driven cellular proliferation. MCF-7 548 
cells were reverse transfected with wtESR1 (ESR1) alone or in combination with either wtESR2 549 
(ESR2) or ESR2 c.948delT (948ΔT) for 24h and then treated with 10nM E2, 100nM E2, or 10nM PPT 550 
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for 72h, compared with vehicle (ethanol) treated controls. Cell proliferation status was quantified by 551 
luciferase assay using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) and expressed 552 
relative to ethanol treated controls. Data presented as mean values ± SE (n = 4). *, P < 0.05; **, P < 553 
0.01; ***, P < 0.001; NS - not significant. 554 
 555 
Figure 4. Diminished ability of ESR2 c.948delT to inhibit wtESR1. Luciferase assays evaluating 556 
transcriptional activity of a transfected ERE by vector only (VO), wtESR1 (ESR1) alone, or in 557 
combination with either wtESR2 (ESR2) or ESR2 c.948delT (948ΔT) mutant at a ratio of 1:3 in (A) 558 
HCT116 and (B) MCF-7 cell lines. Cells were treated with 10nM E2, 10nM PPT or ethanol control as 559 
indicated for 24h prior to cell lysis and luciferase activity measurement. Relative fold change presents 560 
mean values ± SE from at least two independent experiments (n = 4 wells per experiment). *, P < 561 
0.05; **, P < 0.01; ***, P < 0.001. NS - not significant.  562 
 563 
Figure 5. ESR2 c.948delT is associated with elevated RET expression. (A,B) real-time PCR (upper 564 
panel) and Western blot (lower panel) analyses of RET expression levels in HCT116 cells transfected 565 
with wtESR1 (ESR1) alone or in combination with either wtESR2 (ESR2) or ESR2 c.948delT 566 
(948ΔT) and then treated with either (A) 10nM E2 (+) or (B) 10nM PPT (+) compared to ethanol 567 
control (-). Real-time data presented as mean RET mRNA levels ± SE (n = 4). In control experiments 568 
cells were transfected with vector only (VO) as indicated. (C) Representative histological sections 569 
showing immunohistochemical staining for RET (upper panels) with corresponding calcitonin stains 570 
(lower panels) to confirm presence of CCH/MTC. Left - archived slides from individual II:1 showing 571 
areas of intense RET staining (white arrow, upper panel) and area of marked calcitonin staining 572 
indicating presence of CCH (white arrowhead, lower panel) within normal thyroid tissue. Middle - 573 
MTC tumour from individual II:3 showing intense RET expression (white arrowhead, upper panel) as 574 
compared with corresponding normal thyroid tissue (black arrowhead, upper panel). Calcitonin stain 575 
(lower panel) confirms presence of MTC (same panel as in Fig.1B). Right - MEN2 associated MTC 576 
(white arrowhead, upper panel) also showing intense RET expression as compared with 577 
corresponding normal thyroid tissue (black arrowhead, upper panel), for comparison with middle 578 
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panel. Calcitonin stain (lower panel) confirms presence of MTC (white arrowhead, lower panel) with 579 
corresponding normal thyroid tissue also shown (black arrowhead, lower panel). 580 
  581 
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Abbreviations 582 
 583 
MTC medullary thyroid cancer 584 
CCH C cell hyperplasia 585 
ER oestrogen receptor beta 586 
ERE estrogen response element 587 
MEN2 multiple endocrine neoplasia type 2 588 
HPT hyperparathyroidism 589 
SNP single nucleotide polymorphism 590 
NHLBI National Heart, Lung and Blood Institute 591 
EVS exome variant server 592 
CNV copy number variant 593 
SIFT Sorts Intolerant From Tolerant 594 
TCGA The Cancer Genome Atlas 595 
ER oestrogen receptor alpha 596 
E2 17β-estradiol  597 
PPT 4,4’,4’’-(4-propyl-[1H]-pyrazole-1,3,5-triyl(trisphenol) 598 
FFPE formalin-fixed paraffin embedded  599 
PCR polymerase chain reaction 600 
LOH loss of heterozygosity  601 
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COSMIC catalogue of somatic mutations in cancer 602 
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
Figure S1. Pedigree of family with MTC/CCH. Diagnoses marked are from histological 
review following thyroid surgery. The index case (arrowed) presented with MTC age 22 
years. ESR2 c.948delT carriers are marked and the ages (y) at which thyroidectomy was 
undertaken are indicated.    
 
 
  
  
Figure S2. OncoScan® FFPE assay of MTC tumour. Log2 ratio (upper panel) and BAF 
plots (lower panel) showing results from the OncoScan® FFPE Assay Kit for MTC tumour 
from individual II:3.  Data shows no copy number abnormality of either chromosome 10 or 
14. There is some evidence of low level loss of chromosomes 3 and 13. 
    
  
  
 
 
 
Figure S3. ESR2 c.948delT results in reduced mRNA levels.  At 24 hours after 
transfection with either wt ESR2 (ESR2, white diamonds) or ESR2 c.948delT (948ΔT, black 
squares), time 0 hours (h) on x-axis, HCT116 cells were treated with actinomycin D (10 
mg/ml) for 0, 4, 8 and 24 hours. The relative wt ESR2 and c.948delT mRNA levels were 
monitored by RT-qPCR. All values are relative to wt ESR2 mRNA levels at 0 hours (set as 
1). Values represent means ± SE (n = 4) from at least two independent experiments. ESR2 
mRNA expression levels were normalized against the 18S rRNA housekeeping gene. **, P < 
0.01; ***, P < 0.001. NS - not significant. 
 
 
 
 
 
 
AIP DDB2 FANCL PALB2 SLX4 
ALK DICER1 FANCM PHOX2B SMAD4 
APC DIS3L2 FH PMS1 SMARCB1 
ATM EGFR FLCN PMS2 STK11 
BAP1 EPCAM GATA2 PRF1 SUFU 
BLM ERCC2 GPC3 PRKAR1A TMEM127 
BMPR1A ERCC3 HNF1A PTCH1 TP53 
BRCA1 ERCC4 HRAS PTEN TSC1 
BRCA2 ERCC5 KIT RAD51C TSC2 
BRIP1 EXT1 MAX RAD51D VHL 
BUB1B EXT2 MEN1 RB1 WRN 
CDC73 EZH2 MET RECQL4 WT1 
CDH1 FANCA MLH1 RET XPA 
CDK4 FANCB MSH2 RHBDF2 XPC 
CDKN1C FANCC MSH6 RUNX1  
CDKN2A FANCD2 MUTYH SBDS  
CEBPA FANCE NBN SDHAF2  
CEP57 FANCF NF1 SDHB  
CHEK2 FANCG NF2 SDHC  
CYLD FANCI NSD1 SDHD  
 
Table S1. List of genes on TruSight Cancer Panel. 
(http://www.illumina.com/products/trusight_cancer.html) 
 
